Physician medical direction for Florida weight-management, GLP-1, HRT, and TRT practices — patient evaluation, labs, prescribing protocols, monitoring, controlled-substance considerations, and chart review. Physician-led governance across Florida.
Yes, in practice. Medical weight loss involves prescribing (including GLP-1 medications), lab orders, and ongoing clinical management, so a supervising physician must establish protocols, define eligibility, and oversee the providers delivering care — whether the clinic is AHCA-licensed or operating under an exemption. The exact structure depends on ownership, staffing, and services.
An APRN (nurse practitioner) may prescribe and manage weight-loss care within their Florida scope, and depending on the arrangement may practice autonomously or under a collaborative/protocol structure. Whether a separate physician medical director is needed depends on the practice model, the services offered, and applicable Florida law — so the structure should be confirmed for each clinic rather than assumed.
Before prescribing GLP-1 medications (semaglutide, tirzepatide), a comprehensive, patient-specific medical evaluation is expected — history, indication and eligibility, contraindication screening, appropriate baseline labs, and a monitoring and follow-up plan. GLP-1 programs are longitudinal medical care, not a one-time visit, so the evaluation supports ongoing management rather than a single dispense.
In many cases GLP-1 medications can be prescribed via telehealth under Florida’s telehealth law (F.S. 456.47), provided the evaluation is sufficient to establish medical appropriateness and a proper monitoring plan is in place. Appropriateness depends on the patient’s history and risk factors; some situations warrant in-person assessment or additional workup.
Baseline and follow-up labs are set by the supervising physician based on the medications used and the patient’s risk profile — commonly metabolic and glycemic markers, and additional testing where clinically indicated. The point is a defined, physician-approved lab and monitoring schedule with a plan for acting on abnormal results, not a fixed universal panel.
Testosterone therapy generally requires a patient-specific evaluation with confirmatory laboratory testing (including appropriately timed testosterone levels), a documented indication, contraindication screening, and a monitoring plan. Because testosterone is a controlled substance, prescribing carries additional state and federal requirements — so TRT programs need a defensible protocol and physician oversight, not a self-serve model.
Testosterone is a Schedule III controlled substance, so telehealth prescribing is subject to both Florida law and federal (DEA) controlled-substance rules, which are more restrictive than for non-controlled drugs and have been changing. Whether a given TRT program can rely on telehealth depends on the current rules, the evaluation performed, and any in-person requirements — this is an area to confirm carefully with current guidance rather than assume.
Hormone therapy is longitudinal care that expects scheduled follow-up and lab monitoring appropriate to the therapy and the patient — tracking response, safety markers, and any risk indicators — with defined criteria for dose adjustment, hold, or referral. The supervising physician sets the monitoring cadence and reviews it as part of ongoing oversight.
A defensible program defines, in advance, who reviews results, what values trigger a hold or dose change, and when a case escalates to the physician or to in-person or specialist care. Establishing and documenting that escalation pathway — and confirming it is followed — is a core part of medical direction.
The Medical Director establishes and approves treatment protocols and standing orders, defines eligibility and lab/monitoring schedules, sets escalation criteria, aligns provider roles to Florida scope, performs recurring chart review, and keeps the program documented and inspection-ready. Real oversight means reviewing care, not signing a certificate.
Chart review should happen on a defined, recurring cadence set by the Medical Director and scaled to the volume and risk of the program, with prompt review of adverse events or outliers. The goal is a documented, ongoing audit rhythm rather than a one-time check at launch.
When a program prescribes controlled substances (for example, testosterone for TRT), additional requirements apply — including Florida’s prescribing rules, PDMP (E-FORCSE) considerations, stricter telehealth limits, and heightened documentation. Protocols, provider roles, and oversight must be built to those higher standards, which is a key focus of medical direction for hormone practices.
Florida medical director services statewide — Miami, Miami Beach, Fort Lauderdale, West Palm Beach, Orlando, Kissimmee, Tampa, and all of Florida.
Under the medical direction of Armando A. Falcon, MD (FL ME 84789). Serving Miami-Dade and all of Florida. Call or WhatsApp +1 (305) 877-7507.